DREAM: Dapiglutide Phase 2 trial (NCT05788601)
Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Active, not recruiting
- Enrolment
- 54
- estimated
- Start
- 27 Apr 2023 (actual)
- Primary completion
- 24 Apr 2024 (actual)
- Sponsor
- University Hospital, Gentofte, Copenhagen
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Placebo (4 mg and 6 mg) | Placebo comparator | Drug: Placebo | Abdominal s.c. self-administration of placebo content once weekly for 12 weeks. To ensure double-blinding, the placebo arm is divided into a 4-mg and 6-mg arm. But both placebo arms are pooled during data analysis. |
| 4 mg dapiglutide | Active comparator | Drug: Dapiglutide | Abdominal s.c. self-administration of 4 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks until the remaining nine weeks of treatment (12 weeks in total) |
| 6 mg dapiglutide | Active comparator | Drug: Dapiglutide | Abdominal s.c. self-administration of 6 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks to 4 mg and again to 6 mg after six weeks until the remaining six weeks of treatment (12 weeks in total) |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percentage change in body weight (kg) | From week 0 (baseline) to week 12 (end of treatment) |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Body weight reduction ≥ 5% | From week 0 (baseline) to week 12 (end of treatment) |
| Body weight reduction ≥ 10% | From week 0 (baseline) to week 12 (end of treatment) |
| Change in fasting serum/plasma concentrations of gut permeability biomarker (LPS-binding protein (LBP)) | From week 0 (baseline) to week 12 (end of treatment) |
| Change in fasting serum/plasma concentrations of inflammation markers (hs-CRP and IL-6) | From week 0 (baseline) to week 12 (end of treatment) |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated TrialClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.